drugset / Trial / NCT03229200
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Phase 4
Active not recruiting
297 enrolled
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson · collab
NaSingle-groupOpen-labelTreatment
Summary
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Timeline
- Start
- 2017-05-22
- Primary completion
- 2027-05-10
- Completion
- 2027-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |